Clinical trial · Observational
Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRC
Efficacy AND Multiomic Molecular Characterization of Tirellizumab Combined With Anlotinib in in MSS/pMMR Metastatic Colorectal Cancer: Data From a Retrospective Multicenter Study
NCT06573424CI-TRIAL-00089174completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To compare the efficacy and safety of tirellizumab combined with anlotinib in the treatment of mss colorectal cancer. To investigate the effective biomarker of anlotinib combined with tiralizumab
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colon Cancer | Malignant Colon Neoplasm | CURATED_EXACT | 0.92 |
| Immunotherapy | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| anlotinib | Drug | — | UNRESOLVED |
| Tislelizumab+anlotinib | Combination Product | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- combination group
- description
- Patients who have been treated with anlotinib + tislelizumab
- interventionNames
- Combination Product: Tislelizumab+anlotinib
- label
- control group
- description
- Patients who have been treated with anlotinib monotherapy
- interventionNames
- Drug: anlotinib
Primary outcomes (1)
- measure
- PFS
- timeFrame
- 36 months
- description
- Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first)
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * 18-70 years old * Patients with mss colorectal cancer who have been confirmed by pathology and have relapsed or failed multiline therapy * Patients who have been treated with anlotinib monotherapy(12 mg qd, d1-14; 21 days per cycle) or anlotinib(12 mg qd, d1-14; 21 days per cycle)+ tislelizumab(200 mg, once every 3 weeks) * the presence of at least one measurable target lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Exclusion Criteria: * Patients with other malignant tumors * Prior treatment with antirotinib, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or anti-CTLA-4 antibodies or any other antibody or drug that specifically targets T cell co-stimulation or checkpoint pathways * Follow-up was less than 30 days
References
Publications (0)
Data not yet available
No reference posted for this study.